Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Merger agrmnt [a]
Quarterly results
CC transcript
Inv. presentation
Director departure
Appointed director
AMICUS THERAPEUTICS, INC. (FOLD) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates",
"2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this presentation may turn out to be wrong and can be affected by inaccurate..."
05/10/2023 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics, Inc. Consolidated Statements of Operations Three Months Ended March 31, 2023 2022 Net product sales $ 86,270 $ 78,715 Cost of goods sold 6,942 7,582 Gross profit 79,328 71,133 Operating expenses: Research and development 41,499 81,517 Selling, general, and administrative 73,957 58,116 Changes in fair value of contingent consideration payable 251 Loss on impairment of assets — 6,616 Depreciation and amortization 1,257 1,411 Total operating expenses 116,964 146,472 Loss from operations Other income: Interest income 2,199 133 Interest expense Other income 1,902 Loss before income tax Income tax benefit 287 Net loss attributable to common stockholders $ $ Net loss attributable to common stockholders per common share — basic and diluted $ $ Weighted-average common share...",
"2 Forward-Looking Statements This presentation contains"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this presentation may turn out to be wrong and can be affected by inaccurate ..."
11/07/2022 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates",
"2 3 4 5"
08/04/2022 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Second Quarter 2022 Financial Results",
"2Q22 Financial Results Conference Call & Webcast August 4, 2022 At the Forefront of Therapies for Rare Diseases"
05/09/2022 8-K/A Quarterly results
05/09/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
11/09/2021 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Updates",
"2 3 4 5"
08/05/2021 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Second Quarter 2021 Financial Results and Corporate Updates",
"2Q21 Financial Results Conference Call & Webcast August 5, 2021"
05/10/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
11/05/2020 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates",
"2 3 4 5"
08/10/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/02/2020 8-K Quarterly results
11/14/2019 8-K Quarterly results
08/08/2019 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Second Quarter 2019 Financial Results and Corporate Updates",
"August 8, 2019 Conference Call Presentation Materials"
05/08/2019 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces First Quarter 2019 Financial Results and Corporate Updates",
"1Q19 Financial Results Conference Call"
02/28/2019 8-K Quarterly results
11/05/2018 8-K Investor presentation, Quarterly results
Docs: "U.S. U. S. INDICATIONS AND USAGE",
"DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL"
08/07/2018 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Updates",
"2 189,053,214 FINANCIAL GUIDANCE FY18"
05/08/2018 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces First Quarter 2018 Financial Results and Corporate Updates",
"May 8, 2018 Conference Call Presentation Materials"
11/08/2017 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Third Quarter 2017 Financial Results and Corporate Updates",
"November 8, 2017 Conference Call Presentation Materials"
08/07/2017 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Second Quarter 2017 Financial Results and Corporate Updates",
"August 7, 2017 Conference Call Presentation Materials"
05/09/2017 8-K Form 8-K - Current report
11/07/2016 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Third Quarter 2016 Financial Results and Corporate Updates",
"November 7, 2016 Conference Call Presentation Materials"
08/09/2016 8-K Form 8-K - Current report
05/03/2016 8-K Form 8-K - Current report
11/03/2015 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Third Quarter 2015 Financial Results and Corporate Updates",
"November 3, 2015 Conference Call Presentation Materials"
08/05/2015 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Second Quarter 2015 Financial Results and Corporate Updates",
"August 5, 2015 Conference Call Presentation Materials"
05/05/2015 8-K Quarterly results
Docs: "Amicus Therapeutics Announces First Quarter 2015 Financial Results and Corporate Updates"
11/06/2014 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Updates",
"November 6, 2014 Conference Call Presentation Materials"
08/07/2014 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Second Quarter 2014 Financial Results and Corporate Updates",
"August 7, 2014 Conference Call Presentation Materials"
05/05/2014 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces First Quarter 2014 Financial Results and Corporate Updates",
"May 5, 2014 Conference Call Presentation Materials"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy